Comparison of antidepressant efficacy-related SNPs among Taiwanese and four populations in the HapMap database

Journal of the Formosan Medical Association

Volumn 110, Issue 7, 2011, Pages 478-482

  Chi, Mei Hung ^a   Lee, Sheng Yu ^a   Chang, Hui Hua ^c   Yang, Yen Kuang ^a,b   Lin, Eugene ^d   Chen, Po See ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d VITA GENOMICS INC   (Taiwan)

Author keywords

Antidepressants; HapMap; Pharmacogenetics; Single nucleotide polymorphisms

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN BETA 3 SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; INTERLEUKIN 1BETA; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; HAPLOTYPE MAP; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PHARMACOGENETICS; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN; TREATMENT RESPONSE;

EID: 79960793481     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(11)60071-5     Document Type: Article

References (21)

1. Drago A, De Ronchi D, Serretti A. Pharmacogenetics of antidepressant response: an update. Hum Genomics 2009; 3:257-74.
2. Laje G, Perlis RH, Rush AJ, et al. Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv 2009;60:1446-57.
3. Lin E, Chen PS. Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics 2008;9:935-46.
4. Preskorn SH. Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future. J Psychopharmacol 2006;20:85-94.
5. Yoshida K, Higuchi H, Kamata M, et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol 2007;21:650-6.
6. Lee HJ, Cha JH, Ham BJ, et al. Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J 2004;4:29-33.
7. Zill P, Baghai TC, Zwanzger P, et al. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 2000;11:1893-7.
8. Kato M, Fukuda T, Wakeno M, et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006;53:186-95.
9. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006;78:804-14.
10. Yu YW, Chen TJ, Hong CJ, et al. Association study of the interleukin-1 beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacology 2003; 28:1182-5.
11. Baune BT, Dannlowski U, Domschke K, et al. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol Psychiatry 2010;67:543-9.
12. Lin E, Chen PS, Chang HH, et al. Interaction of serotoninrelated genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1167-72.
13. Hong Ng C, Norman TR, Naing KO, et al. A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients. Int Clin Psychopharmacol 2006;21:87-92.
14. Rahemtulla T, Bhopal R. Pharmacogenetics and ethnically targeted therapies. BMJ 2005;330:1036-7.
15. The International HapMap Project. Nature 2003;426: 789-96.
16. Marsh S, Kwok P, McLeod HL. SNP databases and pharmacogenetics: great start, but a long way to go. Hum Mutat 2002;20:174-9.
17. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-33; quiz 4-57.
18. Website available at http://www-genome.wi.mit.edu/cgibin/primer/primer3_http://www.cgi.
19. Serre D, Montpetit A, Pare G, et al. Correction of population stratification in large multi-ethnic association studies. PLoS ONE 2008;3:e1382.
20. Kahn JD. Pharmacogenetics and ethnically targeted therapies: racial drugs need to be put in context. BMJ 2005; 330:1508; author reply.
21. Robertson GR, Grant DM, Piquette-Miller M. Pharmacogenetics of pharmacoecology: which route to personalized medicine? Clin Pharmacol Ther 2009;85:343-8.